Drugs / ASP2390
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04184895 | Sep 2020 → Dec 2022 overdue | house allergic alveolitis | Astellas Pharma Global Development, Inc. | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ASP2390 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04184895 ↗ |
| Route | Other | “Intradermal” NCT04184895 ↗ |